Search

A recent study conducted by a researcher at Eulji University in Seoul, South Korea, has found that regular alpha-fetoprotein (AFP) testing can improve curative treatment and survival rates for patients with hepatocellular carcinoma (HCC), a type of liver cancer. The study analyzed data from 185,316 HCC patients registered between 2008 and 2018, with a focus on mortality and curative treatments. The results showed that frequent AFP testing was associated with a 6% relative improvement in survival, and patients who underwent AFP testing three or more times within two years prior to HCC diagnosis had higher rates of liver transplantation or hepatectomy. The study suggests that integrating frequent AFP testing with ultrasonography could lead to early detection and better access to curative treatments, particularly for patients with hepatitis B. [Extracted from the article]

For more information on this research see: Diagnostic performance of the fibrosis-4 index and the NAFLD fibrosis score for screening at-risk individuals in a health check-up setting. Keywords: Diagnostics and Screening; Health and Medicine; Hepatology EN Diagnostics and Screening Health and Medicine Hepatology 5487 5487 1 10/09/23 20231013 NES 231013 2023 OCT 13 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Researchers detail new data in hepatology. [Extracted from the article]

A recent study from Hanyang University in Seoul, South Korea, explored the use of the Fibrosis-4 (FIB-4) index as a screening tool for liver fibrosis in patients under 65 years of age with type 2 diabetes mellitus (T2DM). The research found that while the diagnostic performance of FIB-4 was suboptimal in T2DM patients, it still holds value as a screening tool in this specific age group. The study compared the diagnostic performance of FIB-4 in T2DM and non-T2DM patients and concluded that its limited use in individuals under 65 with T2DM could be beneficial. [Extracted from the article]

Research from Hanyang University in Seoul, South Korea, has developed a modified FIB-4 index specifically tailored for diabetic patients with metabolic dysfunction-associated steatotic liver disease (MASLD) to improve diagnostic accuracy for advanced hepatic fibrosis in Type 2 diabetes mellitus (T2DM) patients. The new model, called the Diabetes Fibrosis Index, showed superior diagnostic accuracy compared to the original FIB-4 index, with a higher negative predictive value across all age groups in the diabetic population. This study highlights the importance of personalized diagnostic tools for managing hepatic fibrosis in T2DM patients with MASLD. [Extracted from the article]

A recent study conducted at Stanford University Medical Center focused on the real-world effectiveness and tolerability of direct-acting antiviral treatment for chronic hepatitis C patients. The study included 15,849 patients from various regions, with a diverse demographic breakdown. Overall, the sustained virological response rate was 96.9%, with slightly lower rates for certain genotypes and patient characteristics. The research concluded that even in patients with cirrhosis and prior treatment experience, the response rates remained high, emphasizing the efficacy of the treatment. [Extracted from the article]

A recent study conducted by researchers at the Catholic University of Korea focused on the use of modified quick sequential organ failure assessment (m-qSOFA) to identify high-risk patients with acutely deteriorated chronic liver disease (CLD), particularly those with acute-on-chronic liver failure (ACLF). The study analyzed data from the Korean Acute-on-Chronic Liver Failure (KACLiF) and the Asian Pacific Association for the Study of the Liver ACLF Research Consortium (AARC) cohorts. The findings showed that patients with high m-qSOFA had lower transplant-free survival rates and higher organ failure development compared to those with low m-qSOFA. The study concluded that baseline and dynamic changes in m-qSOFA can help identify CLD patients at a high risk of developing organ failure and short-term mortality. [Extracted from the article]

A recent study conducted by CHA University in South Korea found that extrahepatic malignancies, or cancers that occur outside of the liver, are the leading cause of death in patients with chronic hepatitis B (CHB) who do not have cirrhosis. The study analyzed data from over 400,000 patients with CHB and found that mortality rates related to hepatocellular carcinoma (HCC) decreased, while mortality rates related to extrahepatic malignancies increased in the antiviral era. These findings highlight the importance of monitoring and addressing extrahepatic malignancies in patients with CHB. [Extracted from the article]

However, for F3-4 fibrosis, the AUROCs of all 3 NITs were generally higher in older (>60 years), nonobese (BMI <25 kg/m2), and non-diabetic patients, although overall the best performance was observed with FIB-4 among nonobese (BMI <25) diabetic patients (AUROC, 0.92). Keywords: Aichi; Japan; Asia; Bariatrics; Diagnostics and Screening; Health and Medicine; Liver Diseases and Conditions; Non-Alcoholic Fatty Liver Disease; Nutritional and Metabolic Diseases and Conditions; Obesity; Obesity and Diabetes EN Aichi Japan Asia Bariatrics Diagnostics and Screening Health and Medicine Liver Diseases and Conditions Non-Alcoholic Fatty Liver Disease Nutritional and Metabolic Diseases and Conditions Obesity Obesity and Diabetes 86 86 1 06/12/23 20230612 NES 230612 2023 JUN 12 (NewsRx) -- By a News Reporter-Staff News Editor at Diabetes Week -- Investigators publish new report on Liver Diseases and Conditions - Non-Alcoholic Fatty Liver Disease. [Extracted from the article]

Keywords: Seoul; South Korea; Asia; Digestive System Diseases and Conditions; Fatty Liver; Fatty Liver Disease; Health and Medicine; Hepatic Fibrosis; Liver Diseases and Conditions; Risk and Prevention EN Seoul South Korea Asia Digestive System Diseases and Conditions Fatty Liver Fatty Liver Disease Health and Medicine Hepatic Fibrosis Liver Diseases and Conditions Risk and Prevention 448 448 1 05/29/23 20230530 NES 230530 2023 MAY 29 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- Investigators publish new report on Liver Diseases and Conditions - Fatty Liver Disease. Seoul, South Korea, Asia, Digestive System Diseases and Conditions, Fatty Liver, Fatty Liver Disease, Health and Medicine, Hepatic Fibrosis, Liver Diseases and Conditions, Risk and Prevention. [Extracted from the article]

2024 NOV 9 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on Liver Diseases and Conditions - Chronic Hepatitis C Virus [...]

2022 DEC 3 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on Disease Attributes - Disease Progression is now available. [...]

2020 SEP 12 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on Liver Diseases and Conditions - Chronic Hepatitis B [...]

2020 FEB 15 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on liver cancer is now available. According to news [...]